Results from the TITAN-RCC clinical trial to assess tailored immunotherapy for patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend.

TITAN-RCC is a large phase 2 study investigating tailored immunotherapy for people with advanced RCC. Patients started with nivolumab monotherapy. The ipilimumab plus nivolumab combination was given to patients who didn’t respond to nivolumab monotherapy as an “immunotherapeutic boost” to improve efficacy and reduce adverse events.

Overall response rate was improved from 28.7% to 37.0% with the addition of ipilimumab when given as a first-line treatment, and from 18.2% to 28.3% when given as a second-line treatment. There were no new safety concerns.

TITAN-RCC is the first study to assess the impact of a tailored approach using ipilimumab as an immunotherapeutic boost to nivolumab monotherapy. This study provides further evidence to the added value of ipilimumab in combination with nivolumab in advanced RCC. The patients continue to be followed to assess the duration and nature of response.

Read more in UroToday here